Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid
Biomolecules · 2026
DOI: 10.3390/biom16020182 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Biomolecules, 2026. Verfasst von Shirin Emtenani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Autoantibodies, Laminin, Complement Inactivating Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation (DFG) through the Schles-336 wig-Holstein Excellence Cluster Precision Medicine in Chronic Inflammation, CRU 303 Pemphigoid Diseases, CRC 1526 Pathomechanisms of Antibody-338 mediated Autoimmunity.
Abstract (Originalsprache)
Anti-p200 pemphigoid is an autoimmune blistering disease (AIBD) caused by autoantibodies against laminin β4 and/or γ1, and clinically resembles bullous pemphigoid (BP) as well as the inflammatory variant of epidermolysis bullosa acquisita (EBA). All three diseases show IgG and/or C3 deposition along the cutaneous basement membrane zone (BMZ). Although complement activation is central to BP and EBA pathogenesis, its role in anti-p200 pemphigoid remains unclear. To investigate this, we analyzed inflammatory infiltrates in lesional and perilesional skin from anti-p200 pemphigoid patients (n = 11), revealing a neutrophil-predominant pattern, with mixed neutrophil–eosinophil infiltrates in 81% of cases, which contrasted with the eosinophil-rich infiltrates typical of BP. Infiltrating neutrophils expressed C5aR1 and C5aR2. Complement fixation test (CFT) of patient sera demonstrated C3c deposition at the BMZ in 40% (20/50) of anti-p200 pemphigoid cases and 87% (13/15) of BP cases. Patients in both cohorts could be stratified into high, mild, and non-complement-fixating groups. Pharmacological inhibition of C1s (sutimlimab), C3 (compstatin), C5 (tesidolumab), or C5aR1 (avacopan) significantly blocked C3c or C5 deposition in vitro. These findings indicate that selective blockade of the classical, alternative, or terminal complement pathways effectively prevents BMZ complement deposition, highlighting pathway-specific complement inhibition as a potential therapeutic strategy for anti-p200 pemphigoid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lübeck Institute of Experimental Dermatology, University of Lübeck, 23562 Lübeck, Germany.
- Department of Dermatology, Schleswig-Holstein University Hospital, Campus Lübeck, 23562 Lübeck, Germany.
- Department of Dermatology, University of Oldenburg, 26129 Oldenburg, Germany.
ORCID-Profile: Shirin Emtenani, Nina van Beek
Förderung
- German Research Foundation (DFG) through the Schles-336 wig-Holstein Excellence Cluster Precision Medicine in Chronic Inflammation
- CRU 303 Pemphigoid Diseases
- CRC 1526 Pathomechanisms of Antibody-338 mediated Autoimmunity
- University of Lübeck
- German Research Foundation (DFG)
Zitieren
APA
Emtenani, S., Rastegar Lari, T., Kiehne, C., van Beek, N., Holtsche, M. M., & Schmidt, E. (2026). Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid. Biomolecules. https://doi.org/10.3390/biom16020182
Vancouver
Emtenani S, Rastegar Lari T, Kiehne C, van Beek N, Holtsche MM, Schmidt E. Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid. Biomolecules. 2026. doi:10.3390/biom16020182
BibTeX
@article{Emtenani2026,
author = {Emtenani, Shirin and Rastegar Lari, Tina and Kiehne, Charlotte and van Beek, Nina and Holtsche, Maike M and Schmidt, Enno},
title = {Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16020182}
}
EUVIMED